General Information

• HIV and Kidney Disease (AIDS InfoNet) and Spanish version
• The Kidneys (AIDSmap)
• Kidney Disease Tests (labtestsonline) – page with links to fact sheets on the many types of tests used to monitor the function of the kidneys and urinary tract

Selected Recent Articles

• Three Non-AIDS Illnesses Tied to Cognitive Impairment in Men with HIV.  (September 2016, TheBodyPro)
• For Injection Drug Users With HIV, Higher Risk of Liver/Kidney Disease — But Not Other Non-AIDS Ills.  (August 2016, TheBodyPro)
• Kidney and Bone Markers Improve in Patients With Renal Impairment After Switch from TDF to TAF.  (August 2016, TheBodyPro)
• Poor kidney function associated with increased cardiovascular risk for people with HIV.  (August 2016, AIDSmap)
• Slow But Steady Increase in Kidney Risk Observed With TDF, Atazanavir, Lopinavir.  (August 2016, TheBodyPro)
• Kidney Function Better Over 2 Years With Immediate ART in START Trial.  (August 2016, TheBodyPro)
• Bone loss partially recovers after stopping PrEP, twice-yearly kidney monitoring is enough for most.  (July 2016, AIDSmap)
• Studies examine switch to TAF-based regimens in patients with renal impairment.  (July 2016, Healio)
• Starting Treatment With First-Line Protease Inhibitors May Increase Kidney Disease Risk.  (July 2016, TheBodyPro)
• Switching from tenofovir DF to TAF improves bone and kidney safety.  (July 2016, AIDSmap)
• TAF-based regimen demonstrates safety, efficacy in patients with diabetes, renal impairment.  (June 2016, Healio)
• New Tenofovir Easy on the Kidneys.  (June 2016, Medpage Today)
• Tenofovir alafenamide works well against hepatitis B with less effect on bones and kidneys.  (April 2016, AIDSmap)
• Serious kidney problems are rare with PrEP, but increase with older age and better adherence.  (April 2016, Project Inform)
• Hepatitis C Cure is Linked to Lowered Risk of Death, Kidney Disease and Diabetes in Those With HIV.  (March 2016, Poz)
• Does Hep C Exposure Raise the Risk of Kidney Disease and Osteoporosis in People With HIV?  (March 2016, Poz)
• Frequent Cocaine Injection Among people with HIV and Hepatitis C Raises the Risk of Chronic Kidney Impairment. (March 2016, Poz)
• Switching to emtricitabine/tenofovir alafenamide (F/TAF) maintains viral suppression with better bone and kidney safety.  (February 2016, TheBody); related coverage from Project Inform
• Truvada as PrEP against HIV leads to modest decline in kidney function (Poz); related coverage from AIDSmap, Beta Blog, and in CROI abstract 1 and abstract 2
• HIV Meds Can Cause Cumulative Reduction in Kidney Function.  (December 2015, Poz)
• Tenofovir alafenamide single-tablet regimen shows good efficacy with improved kidney and bone safety.  (October 2015, AIDSmap)
• Inflammation Markers Tied to Worse Kidney Function in Men Taking Antiretroviral Therapy.  (October 2015, TheBodyPro)
• Single-Tablet HIV Regimen Containing Tenofovir Alafenamide Improves Bone and Kidney Safety.  (September 2015, TheBodyPro)
• Updated Tenofovir Is Safer for Bones and Kidneys.  (July 2015, Poz)
• Switching to new tenofovir alafenamide keeps virus in check and improves kidney and bone health.  (July 2015, AIDSmap)
• Lower daily tenofovir dose of 150mg safe and effective in people with moderate renal impairment.  (May 2015, AIDSmap)
• Merck’s Hep C Therapy Cures 99% of Those with Kidney Disease.  (April 2015, Hepmag)
• New form of tenofovir TAF looks to be easier on bone and kidney health to the current TDF.  (March 2015, Project Inform)
• The Kidney at CROI 2015.  (March 2015, NATAP)
• Several HIV Meds Steadily Raise Kidney Disease Risk Over Time.  (March 2015, Poz)
• Tenofovir, boosted atazanavir and boosted lopinavir are associated with cumulative risk of developing chronic kidney disease.
  (February 2015, AIDSmap)
• Tenofovir alafenamide equally effective but safer for kidneys and bones than current formulation.  (February 2015, AIDSmap)
• Exposure to antiretrovirals and development of chronic kidney disease – D:A:D Study Group.  (February 2015, NATAP)
• Poor kidney function predicts neurocognitive decline with undetectable viral load.  (February 2015, NATAP)
• Patients with HIV can safely receive kidneys from deceased HIV-positive donors, with good five-year survival rates.  (February 2015, AIDSmap)
• Kidneys From Donors With HIV Transplant Well Into HIV-Positive Recipients.  (February 2015, Poz)
• Age-Related Diseases Not Occurring Earlier for People With HIV.  (November 2014, Poz)
• Long-Term Tenofovir Use Associated With Higher Rates of Kidney Problems.  (November 2014, TheBodyPro)
• Cobicistat Safe for HIV-Positive Patients with Mild to Moderate Renal Impairment.  (October 2014, TheBody)
• People With HIV and Kidney Problems Should Avoid Viread (Tenofovir)  (October 2014, Poz)
• U.S. HIV guidelines for management of chronic kidney disease.  (September/October 2014, HIV Treatment Bulletin)
• HIV infection associated with an increased risk of the diseases of ageing.  (September 2014, AIDSmap)
• Guidelines Advise Against Tenofovir for HIV Patients With Kidney Disease.  (September 2014, TheBodyPro)
• Tenofovir Tied to Kidney Damage in Those With Low Body Weight.  (September 2014, Poz)
• Tenofovir HIV PrEP causes no long-term harm to kidneys.  (May 2014, AIDSmap)
• New Kidney Risk Score System May Guide HIV Med Choices.  (April 2014, Poz)
• Risk score can help predict which people living with HIV have highest risk of kidney disease during tenofovir treatment.  (March 2014, AIDSmap)
• Stopping TDF Before Renal Impairment Boosts Chance of Improving eGFR. (March 2014, NATAP)
• Truvada as PrEP Appears Not to Damage Kidneys.  (February 2014, Poz)
• Truvada PrEP does not harm the kidneys, trial shows.  (February 2014, AIDSmap)
• New Tenofovir Has Lower Dose, Is Kinder to Kidneys and Bones.  (September 2013, Poz)
• New tenofovir formulation works equally well with less effect on kidneys and bones.  (September 2013, AIDSmap)
• Loss of kidney function in older people with HIV underlines need for earlier treatment.  (September 2013, AIDSmap)
• First Kidney Transplant Between People With HIV Is a Success.  (August 2013, Poz)
• Cleared HCV infection associated with increased risk of kidney disease in people with HIV.  (August 2013, AIDSmap)
• People With HIV Have High Rates of End-Stage Renal Disease.  (July 2013, Poz)
• Kidney problems linked to tenofovir use, improve with switch to abacavir.  (July 2013, AIDSmap)
• The Kidney at CROI 2013.  (March 2013, NATAP)
• Cardiovascular Disease and Co-morbidities in HIV.  (March 2013, NATAP)
• HIV-Infected Adults Are at Greater Risk for Myocardial Infarction (MI), End-stage Renal Disease (ESRD), and Non-AIDS-defining Cancers, But Events Occur at Similar Ages Compared to HIV-uninfected Adults (VA)  (March 2013, NATAP)
• New Tenofovir Prodrug Shows Potency, Plus Better Kidney and Bone Safety Than Current Formulation.  (March 2013, TheBodyPro)
• New tenofovir prodrug virologically equivalent to TDF – and easier on kidneys and bone.  (March 2013, NATAP)
• Higher MI, ESRD, Cancer Rates With HIV – But Not Necessarily at Younger Age.  (March 2013, NATAP)
• Tenofovir, atazanavir/ritonavir and Kaletra associated with kidney problems in patients taking HIV therapy.  (February 2013, AIDSmap)
• Tenofovir May Raise Risk of Kidney Damage, but Effect Tapers Over Time.  (February 2013, Poz)
• Conditions Outside of AIDS Pose Significant Threat to People With HIV.  (January 2013, Poz)